Compass Pathways' Psilocybin Achieves Phase 3 Success for Treatment-Resistant Depression
TL;DR Summary
Compass Pathways announced positive results from its Phase 3 trial of COMP360, a synthetic psilocybin formulation, showing significant reduction in depression symptoms in treatment-resistant depression patients, with safety findings consistent with previous studies. The company plans to discuss these results with the FDA and continues its research with further trials.
- Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Business Wire
- Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial Yahoo Finance
- Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle Psychedelic Alpha
- Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed Fierce Biotech
- Psilocybin Safe, Effective for TRD: Phase 3 Data Medscape
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
8 min
vs 9 min read
Condensed
97%
1,677 → 50 words
Want the full story? Read the original article
Read on Business Wire